CN116549559A - 一种治疗心律失常的中药组合物及其制备方法和应用 - Google Patents
一种治疗心律失常的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116549559A CN116549559A CN202310538756.0A CN202310538756A CN116549559A CN 116549559 A CN116549559 A CN 116549559A CN 202310538756 A CN202310538756 A CN 202310538756A CN 116549559 A CN116549559 A CN 116549559A
- Authority
- CN
- China
- Prior art keywords
- parts
- decoction
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 96
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 206010003119 arrhythmia Diseases 0.000 title claims abstract description 45
- 230000006793 arrhythmia Effects 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 18
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 235000008434 ginseng Nutrition 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 235000014066 European mistletoe Nutrition 0.000 claims abstract description 14
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 14
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims abstract description 14
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 14
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 13
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 12
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 12
- 235000005412 red sage Nutrition 0.000 claims abstract description 12
- 244000003416 Asparagus officinalis Species 0.000 claims abstract description 11
- 235000005340 Asparagus officinalis Nutrition 0.000 claims abstract description 11
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 11
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 11
- 241000606266 Nardostachys Species 0.000 claims abstract description 10
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 4
- 244000152640 Rhipsalis cassutha Species 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000000706 filtrate Substances 0.000 claims description 23
- 241000208340 Araliaceae Species 0.000 claims description 17
- 208000009729 Ventricular Premature Complexes Diseases 0.000 claims description 16
- 241000724115 Ziziphus lotus Species 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 8
- 240000008866 Ziziphus nummularia Species 0.000 claims description 7
- 206010042602 Supraventricular extrasystoles Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 41
- 238000011282 treatment Methods 0.000 abstract description 41
- 230000002028 premature Effects 0.000 abstract description 21
- 230000008602 contraction Effects 0.000 abstract description 17
- 230000002861 ventricular Effects 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000008901 benefit Effects 0.000 abstract description 9
- 230000036471 bradycardia Effects 0.000 abstract description 3
- 230000004069 differentiation Effects 0.000 abstract description 2
- 240000002853 Nelumbo nucifera Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 description 23
- 206010033557 Palpitations Diseases 0.000 description 16
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 241000221012 Viscum Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 241001106477 Paeoniaceae Species 0.000 description 7
- 230000001746 atrial effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 6
- 230000003288 anthiarrhythmic effect Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- 239000003416 antiarrhythmic agent Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000002936 tranquilizing effect Effects 0.000 description 5
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 208000006083 Hypokinesia Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 239000009877 shengmai Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 3
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 3
- 229940039750 aconitine Drugs 0.000 description 3
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 3
- 210000000467 autonomic pathway Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- -1 paeonol Chemical class 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 241000209020 Cornus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 241000405414 Rehmannia Species 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
- 206010049447 Tachyarrhythmia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002327 cardiovascular agent Substances 0.000 description 2
- 229940125692 cardiovascular agent Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002565 electrocardiography Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 229960000939 metoprolol succinate Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000036279 refractory period Effects 0.000 description 2
- 239000008659 shensongyangxin Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000003663 ventricular fibrillation Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000012856 weighed raw material Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 235000001808 Ceanothus spinosus Nutrition 0.000 description 1
- 241001264786 Ceanothus spinosus Species 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 208000013875 Heart injury Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- AJPXZTKPPINUKN-UHFFFAOYSA-N Isoliensinin Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-UHFFFAOYSA-N 0.000 description 1
- AJPXZTKPPINUKN-FIRIVFDPSA-N Isoliensinine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-FIRIVFDPSA-N 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010040738 Sinus arrest Diseases 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010001902 amaurosis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940045511 barium chloride Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000004375 bundle of his Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000006860 carbon metabolism Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000011297 radiofrequency ablation treatment Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗心律失常的中药组合物及其制备方法和应用,所述中药组合物包括以下配比的原料药制备而成:生晒参3‑6份,天冬6‑18份,麦冬6‑30份,五味子6‑12份,槲寄生15‑40份,酒萸肉6‑18份,丹参6‑20份,赤芍6‑12份,酒当归6‑18份,甘松6‑18份,酸枣仁6‑18份,生龙骨6‑18份,莲子心3‑6份。本发明的中药组合物(生脉宁心方)积极发挥中医药整体辨治的优势,相比其他药物配方科学,提高了用药安全性,并对于快速性及缓慢性心率伴发的室性期前收缩、室上性期前收缩均有治疗效果,可弥补对于这类临床常见心律失常病种治疗措施上的不足。
Description
技术领域
本发明属于中药技术领域,具体地说,涉及一种治疗心律失常的中药组合物(生脉宁心方),用于治疗室性期前收缩、室上性期前收缩,及该中药组合物的制备方法和应用。
背景技术
心律失常是指心脏冲动的频率、节律、起源部位、传导速度或激动次序的异常,是心血管疾病中最常见的病症之一。患者可出现心悸、胸闷、头晕、乏力、出汗等症状,进一步发展可导致黑矇、晕厥,严重者甚至发生猝死。冲动提前传导时的心律异常称为期前收缩,根据异位起搏点不同,可分为室性和室上性两大类。室性期前收缩(简称室早),是指窦性激动未到达之前,由希氏束及其分支以下心室肌的异位兴奋灶提前除极产生的心室期前收缩。室早的发病率随年龄增长而增加,在11岁以下儿童中其发病率<1%,而在>75岁的人群中可高达69%,部分发作频发室早会诱发心肌病和左心室功能障碍或加重潜在心肌病,当合并结构性心脏病时可能会诱发心动过速、心室颤动等疾病进而增加猝死风险。室上性期前收缩,是指心房或房室交界区的异位兴奋灶提前除极而产生的心脏提前搏动,包括房性期前收缩(简称房早)和房室交界性期前收缩。其中,房早伴室内差异性传导通常提示无器质性心脏损伤,反复频繁的房早未得到有效控制可引发心房颤动,是卒中的重要危险因素之一。
目前西医抗心律失常的治疗主要以药物治疗和外科治疗两种方式为主。抗心律失常药物疗效有限,因其存在抑制窦房结功能、阻滞房室传导等药理作用机制,在抗心律失常的同时也可能会致新的心律失常,如维拉帕米可能致窦性停搏、普罗帕酮可能致严重房室传导阻滞等;外科治疗方面,目前有导管射频消融术、埋藏式心律转复除颤器(ICD)植入术、起搏器植入术等技术,对部分急重病例获效显著,但仍然存在价格昂贵、有创性伤害、患者依从性差等问题。
室性期前收缩、室上性期前收缩根据其症状可归属于中医学中“心悸”、“怔忡”等范畴。近年来,中医药因具有多成分、多途径、多靶点的综合调治作用,在抗心律失常方面体现出一定优势。
目前,常用的中成药参松养心胶囊就是以生脉饮为基础方联合现代制药工艺研制而成的,但其组成成分中土鳖虫具有毒性可致头晕、呕吐、过敏等不良反应,因此用药时存在一定的安全风险;另组成中的黄连,其所含小檗碱可能致脑损伤。
目前,一些中药也可缓解如上列出的两种心律失常症状,但存在一定的不足或可改进的空间。
例如,中国专利申请202211059623.7公开了一种用于治疗心律失常的中药制剂,所述心律失常是指室上性期前收缩、阵发性心房颤动、室性期前收缩,包括以下质量份数的原料药:熟地黄15-30份、全蝎3-6份、丹参10-30份、陈皮10-15份。该专利所述药物组分中“全蝎”有毒性,临床应用中可能存在安全风险。
再如,中国专利申请202111129985.4公开了一种治疗快速性心律失常的中药组合物及其制备方法和应用,所述中药组合物可治疗多种室性、室上性心律失常,但该组合物显示出明显的抗快速性心律失常、减慢心律等作用,对于慢心率伴有的室性、室上性心律失常可能没有明显良效。
经方生脉饮由人参、麦冬、五味子三药组成,具有益气复脉、养阴生津的功效,研究表明其含有的71个组分属于心律失常靶点的潜在抑制剂,为该方抗心律失常提供了理论依据。
发明内容
针对现有技术中存在的缺点与不足,本发明的目的在于提供一种治疗心律失常的中药组合物。
目前,中医治疗心律失常能够同时具备使用安全、疗效确切优点的临床药剂较少,在此基础上,本发明的中药组合物(生脉宁心方)积极发挥中医药整体辨治的优势,相比其他药物配方科学,提高了用药安全性,并对于快速性及缓慢性心率伴发的室性期前收缩、室上性期前收缩均有治疗效果,可弥补对于这类临床常见心律失常病种治疗措施上的不足,鉴于此,本发明为心律失常患者提供一种疗效好、安全性高的中药组合物。
本发明的目的还在于提供上述中药组合物的制备方法。
本发明的目的还在于提供上述中药组合物在制备治疗慢性心衰药物中的应用。
本发明的技术方案如下:
一种治疗心律失常的中药组合物,包括以下配比的原料药制备而成:生晒参3-6份,天冬6-18份,麦冬6-30份,五味子6-12份,槲寄生15-40份,酒萸肉6-18份,丹参6-20份,赤芍6-12份,酒当归6-18份,甘松6-18份,酸枣仁6-18份,生龙骨6-18份,莲子心3-6份。
进一步的,所述中药组合物包括以下配比的原料药制备而成:生晒参3-5份,天冬10-15份,麦冬15-20份,五味子6-10份,槲寄生20-30份,酒萸肉10-15份,丹参15-20份,赤芍6-10份,酒当归10-15份,甘松10-15份,酸枣仁10-15份,生龙骨10-15份,莲子心3-5份。
更进一步的,所述中药组合物包括以下配比的原料药制备而成:生晒参3份,天冬15份,麦冬15份,五味子9份,槲寄生30份,酒萸肉10份,丹参15份,赤芍10份,酒当归15份,甘松15份,酸枣仁15份,生龙骨15份,莲子心3份。
进一步的,所述中药组合物的剂型为水煎剂、中药膏剂、丸剂中的任意一种。
更进一步的,所述中药组合物的剂型为水煎剂。
一种治疗心律失常的中药组合物的制备方法,包括:取所述原料药用用水煎煮,取滤液;
所述煎煮包括以下步骤:
将生晒参单独与水混合后进行第一煎煮,得到第一滤渣和第一滤液;
将生龙骨与水混合后进行预煎煮,然后加入其余原料和水进行第二煎煮,得到第二滤渣和第二滤液;
将第二滤渣与水混合后进行第三煎煮,得到第三滤渣和第三滤液;
合并第一滤液、第二滤液、第三滤液得到滤液。
进一步的,所述第一煎煮中,生晒参与水的质量比为1:10~1:40,所述第一煎煮时间为0.5h;
所述预煎煮中,生龙骨和水的质量比为1:8~1:10,所述预煎煮时间为0.5h。
所述第二煎煮中,原料的总质量与再次添加的水的质量比为1:8~1:10,所述第二煎煮时间为1.25-1.5h。
所述第三煎煮中,所述第二滤渣与水的质量比为1:6~1:8,所述第三煎煮的时间为0.5-1.0h。
上述任意一项的中药组合物在制备治疗心律失常的药物中的应用。
进一步的,所述心律失常包括室性期前收缩或室上性期前收缩的心律失常。
进一步的,所述中药组合物的服用方法优选包括:患者每日分早晚温服两次,每次200ml。本发明提供的中药组合物在患者服用7~42d后,24h早搏数量明显减少。
与现有技术相比,本发明的优点如下:
(1)本发明的中药组合物(生脉宁心方)以生晒参、天冬、麦冬、五味子为君药,组益气护脉,养阴生津;槲寄生、酒萸肉相配为臣药,益肾以养心;酸枣仁、生龙骨相伍养心敛汗、安神定志为臣;莲子心清心宁神为臣;丹参、赤芍、当归、甘松相合行气活血,即调和气血为佐,气血以循其常,则心神自归宁静。
全方宗生脉饮“补、清、敛”益气护脉、养阴生津之义,配伍精当,补泻兼施,标本兼顾,契合心悸气阴两虚之病机,使气阴调和、脉复心宁,从而达到抗心律失常治疗作用。经临床验证,该中药组合物治疗不同类型(包括室性期前收缩、室上性期前收缩)的心律失常均有显著疗效,适用于临床的推广应用。
其中,生脉饮(生晒参、麦冬、五味子):研究表明该方可通过降低左心室射血分数、作用于碳代谢、嘌呤代谢、糖类代谢等能量代谢相关通路或通过调节ATP水平来达到对心律失常的治疗作用。
天冬:味甘苦寒,归肺、肾、心经。功效:养阴清肺,滋阴润燥。《本草经集注》记载:“保定肺气,去寒热,养肌肤,益气力,利小便,冷而能补,久服轻身,益气,延年,不饥。”药理学研究发现,天冬含多种单糖、多糖,19种氨基酸、天冬氨基酸与细胞有较强亲和力,可以作为钾、镁离子的载体进入细胞内,对维持血钾、镁,尤其是胞内钾的含量有重要作用,而钾离子可促进细胞除极化,维持心肌收缩能力,同时降低氧耗。
槲寄生:味苦,性甘平,归肝、肾二经。功效:补肝肾、强筋骨、祛风湿、安胎元。现代研究发现槲寄生有扩张冠状动脉、抗室颤的作用,临床槲寄生注射液可用于治疗冠心病、抗心绞痛及抗心律失常;
酒萸肉:味酸涩,微温,归肝、肾二经。功效:补益肝肾、涩精固脱。现代研究表明该药通过延长心肌动作电位时间,提高静息电位绝对值,抑制心肌组织的自律性,从而发挥抗心律失常作用;
丹参:性苦、微寒,归心、心包、肝经。功效:活血调经,祛瘀止痛,凉血消痈,除烦安神。药理研究显示,丹参主含的二萜类成分、酚酸成分、黄酮类成分等有保护血管内皮细胞、扩张冠脉等作用,从而发挥抗心肌缺血、抗心梗、提高心肌的耐缺氧能力,并有镇静、催眠作用;
赤芍:味苦、微寒,归心、小肠经。功效:清热凉血、散瘀止痛。《本草经解》记载:“赤者入心与小肠,心主血,小肠主变化,所以行而不留,主破血也。”现代研究表明,赤芍有效成分丹皮酚等多元酚类,具有抗血小板聚集、抗血栓形成、抗心肌缺血、改善微循环的作用,此外还有保肝、镇静、抗惊厥等作用;
当归:味甘、温,归心、肝、脾经。功效:补血、活血、止痛、润肠。《雷公炮制药性论》记载:“头,止血而上行。身,养血而中守。梢,破血而下流。全,活血而不走。气血昏乱,服之而定,各归所当归,故名。”研究表明,当归的水溶成分中主要是当归总酸,具有类似奎尼丁作用,对氯仿—肾上腺素、乌头碱、氯化钡等诱发的动物药物型心律失常有明显保护作用,其作用机制可能是由于降低心脏兴奋性、延长心肌不应期,减慢传导,消除折返、延长平台期,抑制异位节律点及提高颤阈等多方面作用的结果。
甘松:味辛甘、性温,归脾、胃经。功效:理气止痛,开郁醒脾。现代动物实验表明,甘松具有心肌膜的抑制及延长心房肌动作电位的作用,对抗氯化钠诱发的大鼠心律失常,可抑制异位室性节律,对抗家兔由氯仿-肾上腺素引起的心律失常,直接抑制心肌,延长心房不应期,另具镇静作用、抗惊厥,保护缺血心肌,提高耐缺氧能力等作用;
酸枣仁:味酸、平,归心、肝、胆经。功效:养心安神,敛汗。《长沙药解》记载:“酸枣仁入手少阴心、足少阳胆经。宁心胆而除烦,敛神魂而就寐。”药理证明,酸枣仁有确切的镇静、催眠作用,并有抗心肌缺血、缺氧,对乌头碱、氯化钡所致大鼠心律失常有良好的治疗作用;
生龙骨:味甘、涩、微寒,归心、肝经。功效:平肝潜阳,镇静安神,收敛固涩。药理研究证实生龙骨具镇静、催眠、抗惊厥等作用;
莲子心:苦寒,归心、肾经。功效:清心安神,交通心肾,涩精止血。药理研究表明该药主含莲心碱、甲基莲心碱、异莲心碱等生物碱,动物实验甲基莲心碱可显著抗乌头碱诱发大鼠及哇巴因诱发豚鼠心律失常,还能对抗肾上腺素引起的家兔心律失常,并对电刺激丘脑下诱发之心律失常有预防作用。
(2)本发明的中药组合物(生脉宁心方)以生脉饮(生晒参、麦冬、五味子为主)为基础加减,现代药理学研究表明本发明在广谱抗心律失常的治疗基础上,还具有一定的改善心肌细胞代谢、抗心肌缺氧缺血、调节植物神经功能等心血管保护作用。相较于生脉饮,本发明通过加减后,使得调气和血、清心安神之效更显,且在发挥抗心律失常作用外,同时还具有能够有效改善睡眠质量、抗心肌缺血、调节自主神经功能等保护心血管系统的优势。
具体的,本发明的中药组合物(生脉宁心方)以生脉饮为基础方,加减后共只由13味中药组成,具有益气养阴、调气和血、清心安神之效,且现代药理从药对及单药研究表明,该方药物能通过抑制心肌组织自律性、抑制异位节律点、延长心肌动作电位等机制发挥广谱抗心律失常作用,同时还具有扩冠、抗心肌缺血、调节自主神经功能等保护心血管系统的优势。
(3)本发明的中药组合物(生脉宁心方)用于抗心律失常的治疗,具有经方合用、配方安全、成本低廉、服用方便的特点。
(4)本发明的中药组合物(生脉宁心方)在患者服用后,能够使患者24h内室性期前收缩、室上性期前收缩数量有效减少或者消失,是一种针对心律失常疾病,规范且标准的中药组合物。
具体实施方式
下面结合实施例对本发明做进一步的说明。
实施例1-N本发明中药组合物的制备
实施例1:
本实施例中药组合物按照以下质量份准备原料:
生晒参3份,天冬15份,麦冬15份,五味子9份,槲寄生30份,酒萸肉10份,丹参15份,赤芍10份,酒当归15份,甘松15份,酸枣仁15份,生龙骨15份,莲子心3份。
本实施例的生脉宁心方为水煎剂,其制备方法如下:
按照上述配比的原料取样;
将生晒参与100g水煎煮(第一煎煮)0.5h后分离第一滤渣和第一滤液;
将生龙骨与150g水煎煮(预煎煮)水煎煮0.5h后,加入其余原料和1620g水煎煮(第二煎煮)1.5h后分离第二滤渣和第二滤液;
将第二滤渣与1296g水混合后煎煮(第三煎煮)1.0h,分离第三滤渣和第三滤液;
合并第一滤液、第二滤液和第三滤液得到中药组合物。
优选的,第一煎煮中,生晒参与水的质量比为1:10~1:40。
优选的,预煎煮中,生龙骨和水的质量比为1:8~1:10。
优选的,第二煎煮中,原料的总质量与再次添加的水的质量比为1:8~1:10。
优选的,第三煎煮中,所述第二滤渣与水的质量比为1:6~1:8。
实施例2:
本实施例中药组合物为中药膏剂,其制备方法如下:
按照以下质量份准备原料:生晒参5份,天冬10份,麦冬20份,五味子6份,槲寄生20份,酒萸肉15份,丹参20份,赤芍6份,酒当归10份,甘松10份,酸枣仁10份,生龙骨10份,莲子心5份。
清除杂质、洗净、晒干或烘干。
将上述称量的原料捣碎成粉末状。经100目滤网过滤,得混合物,备用。
加饮用水1500ml浸泡8小时,武火煮开之后,文火煎煮2小时;再煎煮两次,每次的加水量分别为1000ml、800ml,煎煮时间分别为2h、1h;煎煮完毕并过滤,合并滤液。再加入其重量10%的阿胶、蔗糖和蜂蜜辅料混合后浓缩至密度1.5-1.6的稠膏。
制备的中药膏剂的服用方法:早晚各服用一次,每次50~100ml温水冲服。
实施例3:
本实施例中药组合物为丸剂,其制备方法如下:
按照以下质量份准备原料:生晒参6份,天冬6份,麦冬30份,五味子11份,槲寄生40份,酒萸肉6份,丹参18份,赤芍12份,酒当归6份,甘松6份,酸枣仁6份,生龙骨6份,莲子心6份。
清除杂质、洗净、晒干或烘干。
将上述称量的原料捣碎成粉末状。经100目滤网过滤,得混合物,备用。
加入适量的粘合剂或其他辅料,制成球形或者类球形的剂型。其中粘合剂包括水、蜂蜜、酒、醋、药汁,可以制成不同类型的丸剂,例如水丸、蜜丸、水蜜丸、蜡丸等。
临床实验:
一、应用例1
1.病例选择标准:
随机选择临床诊断为期前收缩患者共32人,其中年龄最小的21岁,最大的82岁,平均年龄54岁。病程最短的1月,最长的5年,其中18人有过往治疗史。
2.疾病诊断标准:
主要表现为心悸、胸闷气短、头晕乏力等症状。24h动态心电图诊断为室性/室上性期前收缩的患者。
3.用药方法:
患者服用本发明实施例1提供的中药组合物,每次200ml,早晚各1次,14d为一个疗程,服用1-3个疗程。
4.疗效判断标准:
参照《心血管药物临床试验评价方法的建议》制定
①显效:24h期前收缩次数较治疗前减少>70%;
②有效:24h期前收缩次数较治疗前减少30%-70%;
③无效:24h期前收缩次数较治疗前减少<30%、无变化或加重;
治疗总有效率=(显效例数+有效例数)/总患者数×100%。
5.数据统计及结果
数据统计如表1和表2所示,其中表1为患者服用本发明所述的中药组合物对室性期前收缩的治疗效果;表2为患者服用本发明所述的中药组合物对室上性期前收缩的治疗效果。
表1患者服用本发明所述的中药组合物对室性期前收缩的治疗效果
表2患者服用本发明所述的中药组合物对室上性期前收缩的治疗效果
由表1-表2可知,表1对18例年龄在21-82岁的室性期前收缩患者进行治疗,病情诊断采信正规医院出具的检验报告。在治疗14-42d后,显效8人,有效7人,治疗总有效率占83.33%。临床研究显示,患者对本发明提供的治疗室性期前收缩的中药组合物有比较满意的治疗效果。
表2对14例年龄在30-82岁的室上性期前收缩患者进行治疗,病情诊断采信正规医院出具的检验报告。经过14-42d治疗后,显效9人,有效4人,治疗总有效率占92.86%。临床研究显示,患者对本发明提供的治疗室上性期前收缩的中药组合物有比较满意的治疗效果。
经临床证实,服用本发明提供的中药组合物能使24h室性、室上性期前收缩发作的次数明显减少或消失,可有效缓解患者的心悸、胸闷、气短等症状,可延缓疾病的发展,改善患者的生活质量,并且未出现副作用。
二、应用例2
1.病例选择标准:
随机选择临床诊断为室性期前收缩患者46人,诊断为室上性期前收缩的患者46人,再各自分为治疗组和对照组各23人(考虑有脱落情况,以实际纳入例数为准)。
2.疾病诊断标准:
主要表现为心悸、胸闷气短、头晕乏力等症状。24h动态心电图诊断为室性/室上性期前收缩的患者,心率>60次/分,无支气管哮喘等β阻剂禁忌性疾病。
3.用药方法:
治疗组:患者服用本发明西药琥珀酸美托洛尔47.5mg/日,加服实施例1提供的中药组合物,每次200ml,早晚各1次,14d为一个疗程,服用1-3个疗程。
对照组:患者单纯服用西药琥珀酸美托洛尔47.5mg/日。
两组患者均可在服药方案上给予常规高血压、冠心病等基础疾病药物治疗。
4.疗效判断标准:
参照《心血管药物临床试验评价方法的建议》制定
a)显效:24h期前收缩次数较治疗前减少>70%;
b)有效:24h期前收缩次数较治疗前减少30%-70%;
c)无效:24h期前收缩次数较治疗前减少<30%、无变化或加重;
治疗总有效率=(显效例数+有效例数)/总患者数×100%。
5.数据统计及结果
表3两组室性期前收缩疗效比较
P=0.022
表4两组室上性期前收缩疗效比较
P=0.025
室早组、室上早组两组的疗效情况如表3、表4,对表中疗效例数行卡方检验,均存在统计学差异(P<0.05),说明两组内治疗组减少早搏次数均优于对照组。
三、应用例3
下面通过本发明治疗冠心病伴频发室性期前收缩典型案例3例进一步阐述本发明的显著效果。
案例1
张某,男,79岁,2016年3月于医院体检时查冠脉CTA提示冠心病,因无明显症状未予重视及治疗。2017年于南京A医院体检查动态心电图示:室早7183次。予口服参松养心胶囊+倍他乐克治疗,治疗期间服药有间段。2022年6月因自觉心慌胸闷不适于我院心血管门诊就诊,查24h动态心电图示:室早26760次。嘱其停服决奈达隆,予口服本发明的实施例1的中药组合物治疗9周,心悸明显缓解,胸闷、气短乏力、睡眠改善。2022年8月23日复查动态心电图示:室早0次,偶发房早。自行减量至两日一剂中药。后于9月15日偶然发现脉搏降至40次/分,并出现心悸,转日改回服1日1剂。后门诊间断随诊至2023年2月28日,心悸未作,生活质量较前改善。
案例2
孙某,男,30岁,反复心悸6年余,2021年12月17日查动态心电图提示:24h存在室早7278次。2022年1月3日于我院心血管内科就诊,予口服中药汤剂(党参15g,炙黄芪15g,熟地黄20g,法半夏10g酒萸肉10g,生山药20g,麸炒白术15g,茯苓10g,盐车前子10g,炙甘草6g)及参松养心胶囊治疗1月余,症状好转不显,2022年3月23日复查动态心电图提示:24h存在室早10893次。医生建议进一步行射频消融术治疗,患者拒行手术治疗,仍希望保守药物治疗,遂停中药汤剂,继予参松养心胶囊口服。2022年5月30日于团队门诊就诊,予实施例1的中药组合物口服14天后自觉症状较前有好转,后于外院原方续方,继续治疗1月余,2022年7月27日复查动态心电图提示:24h存在室早2704次。较服药前治疗有效率达75%。随访过程中,患者自诉睡眠、食欲、自汗情况均较前改善,日常生活中心悸不显。
案例3
邓某,男,31岁,自诉2023年2月时感心慌气短,发作时呼吸困难,外院查动态心电图提示:24h室上早3014次。2023年2月27日于团队门诊就诊,予实施例1的中药组合物14付口服后心悸间作,续服14付后,患者自觉心慌症状不显,情绪较前稳定,2023年3月26日复查动态心电图提示:24h室上早472次。治疗有效率可达84%。特别的,该患者既往有肝损害病史,服药前后患者肝功能未见明显变化,肝酶未见升高,进一步提示本方有安全性。
由上述实施例和应用例可知,本发明提供的中药组合物治疗效果好、治愈率高、无毒性成分,可以减少室性期前收缩、室上性期前收缩数量,具有益气养阴,调和气血,清心安神的功效,能够有效抑制疾病的进展,改善患者的生活质量,并具有安全性。
以上的实施例仅为说明本发明的技术思想,不能以此限定本发明的保护范围,凡是按照本发明提出的技术思想,在技术方案基础上所做的任何改动,均落入本发明保护范围之内。
Claims (9)
1.一种治疗心律失常的中药组合物,其特征在于,所述中药组合物包括以下配比的原料药制备而成:生晒参3-6份,天冬6-18份,麦冬6-30份,五味子6-12份,槲寄生15-40份,酒萸肉6-18份,丹参6-20份,赤芍6-12份,酒当归6-18份,甘松6-18份,酸枣仁6-18份,生龙骨6-18份,莲子心3-6份。
2.如权利要求1所述的一种治疗心律失常的中药组合物,其特征在于,所述中药组合物包括以下配比的原料药制备而成:生晒参3-5份,天冬10-15份,麦冬15-20份,五味子6-10份,槲寄生20-30份,酒萸肉10-15份,丹参15-20份,赤芍6-10份,酒当归10-15份,甘松10-15份,酸枣仁10-15份,生龙骨10-15份,莲子心3-5份。
3.如权利要求1所述的一种治疗心律失常的中药组合物,其特征在于,所述中药组合物包括以下配比的原料药制备而成:生晒参3份,天冬15份,麦冬15份,五味子9份,槲寄生30份,酒萸肉10份,丹参15份,赤芍10份,酒当归15份,甘松15份,酸枣仁15份,生龙骨15份,莲子心3份。
4.如权利要求1-3任意一项所述的一种治疗心律失常的中药组合物,其特征在于,所述中药组合物的剂型为水煎剂、中药膏剂、丸剂中的任意一种。
5.如权利要求4所述的一种治疗心律失常的中药组合物,其特征在于,所述中药组合物的剂型为水煎剂。
6.权利要求1所述的一种治疗心律失常的中药组合物的制备方法,其特征在于,取所述原料药用用水煎煮,取滤液;所述煎煮包括以下步骤:
将生晒参单独与水混合后进行第一煎煮,得到第一滤渣和第一滤液;
将生龙骨与水混合后进行预煎煮,然后加入其余原料和水进行第二煎煮,得到第二滤渣和第二滤液;
将第二滤渣与水混合后进行第三煎煮,得到第三滤渣和第三滤液;
合并第一滤液、第二滤液、第三滤液得到滤液。
7.如权利要求6所述的制备方法,其特征在于,所述第一煎煮中,生晒参与水的质量比为1:10~1:40,所述第一煎煮时间为0.5h;
所述预煎煮中,生龙骨和水的质量比为1:8~1:10,所述预煎煮时间为0.5h。
所述第二煎煮中,原料的总质量与再次添加的水的质量比为1:8~1:10,所述第二煎煮时间为1.25-1.5h。
所述第三煎煮中,所述第二滤渣与水的质量比为1:6~1:8,所述第三煎煮的时间为0.5-1.0h。
8.权利要求1-5任意一项的所述的中药组合物在制备治疗心律失常的药物中的应用。
9.权利要求8所述的应用,其特征在于,所述心律失常包括室性期前收缩或室上性期前收缩的心律失常。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310538756.0A CN116549559A (zh) | 2023-05-15 | 2023-05-15 | 一种治疗心律失常的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310538756.0A CN116549559A (zh) | 2023-05-15 | 2023-05-15 | 一种治疗心律失常的中药组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116549559A true CN116549559A (zh) | 2023-08-08 |
Family
ID=87492711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310538756.0A Pending CN116549559A (zh) | 2023-05-15 | 2023-05-15 | 一种治疗心律失常的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116549559A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103623207A (zh) * | 2012-08-23 | 2014-03-12 | 石家庄以岭药业股份有限公司 | 一种中药组合物在制备治疗慢性心衰伴心律失常的药物中的应用 |
CN111298019A (zh) * | 2020-03-11 | 2020-06-19 | 河北省中医药科学院 | 一种治疗快速性心律失常的中药 |
-
2023
- 2023-05-15 CN CN202310538756.0A patent/CN116549559A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103623207A (zh) * | 2012-08-23 | 2014-03-12 | 石家庄以岭药业股份有限公司 | 一种中药组合物在制备治疗慢性心衰伴心律失常的药物中的应用 |
CN111298019A (zh) * | 2020-03-11 | 2020-06-19 | 河北省中医药科学院 | 一种治疗快速性心律失常的中药 |
Non-Patent Citations (1)
Title |
---|
卢健棋等: "中医治疗室性早搏近况", 山西中医, vol. 16, no. 02, 29 February 2000 (2000-02-29), pages 52 - 55 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108310199A (zh) | 一种治疗冠心病心绞痛的中药组合物及其制剂 | |
CN1306951C (zh) | 一种治疗气虚血瘀型胸痹的药物及其制备工艺 | |
CN104489518A (zh) | 治疗神经衰弱的养生粥及制备方法 | |
CN101129469B (zh) | 防治心脑血管疾病的中药组合物 | |
CN116549559A (zh) | 一种治疗心律失常的中药组合物及其制备方法和应用 | |
CN1970050B (zh) | 一种治疗心率失常的药物组合物及其制备方法 | |
CN108938912B (zh) | 防治阵发性房颤的中药组合物及其超微粉水丸剂和应用 | |
CN102755517B (zh) | 一种治疗心律失常的中药贴剂及其制备方法 | |
CN106620253B (zh) | 一种治疗缓慢性心律失常的中药组合物 | |
CN102204956B (zh) | 一种用于中风恢复期的中药组合物及其制备方法 | |
CN100546637C (zh) | 一种治疗冠心病的中药组合物及其制备方法 | |
CN102048939A (zh) | 一种治疗窦性心动过缓药物 | |
CN101342208B (zh) | 一种治疗冠心病、心绞痛、心律失常的中药组合物及其制备方法 | |
CN106138795B (zh) | 治疗早搏的中药组合物及其制备方法 | |
CN101254266A (zh) | 一种治疗心脑血管疾病的药物 | |
CN115120671B (zh) | 一种治疗缓慢性心律失常的中药组合物及其应用 | |
CN113679781B (zh) | 一种治疗快速性心律失常的中药组合物及其制备方法和应用 | |
CN115814020B (zh) | 一种治疗室性心律失常的中药组合物及其应用 | |
KR101600745B1 (ko) | 생약 추출물을 포함하는 신경안정용 약학적 조성물 | |
CN113476526B (zh) | 一种对心房颤动具有治疗作用的中药复方组合物及其制备方法 | |
CN103055122A (zh) | 预防冠脉支架植入术后再狭窄的药物及其制备方法 | |
CN112294901B (zh) | 治疗室上性心律失常的中药组合物及其制备方法和应用 | |
CN110841037B (zh) | 用于治疗昼夜节律紊乱性睡眠障碍的中药药剂及制备方法 | |
CN101152247A (zh) | 用于心脑血管疾病的药物组合物及其制备方法 | |
CN113476557B (zh) | 一种具有治疗糖尿病心脏自主神经病变功效的中药复方组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |